Anthrax Research Study

Currently Enrolling

Fighting Anthrax

Although Anthrax infection is rare in the United States, it can be deadly. Inhalation of Anthrax is the most lethal; Thus, it is very important to have strategies and treatment in place should an exposure occur.

In 1970, the Food and Drug Administration (FDA) approved a vaccine for Anthrax prevention in adults ages 18 to 65. This vaccine has been used for pre-exposed individuals who are at high risk for the infection, such as military personnel. In 2015, the vaccine was approved for post-exposure prophylaxis. The vaccine, BioThrax, causes the body to build up antibodies to fight the Anthrax bacteria and prevent illness.

Our study will be comparing different dosing schedules of BioThrax versus AV7909, which contains a research immune boosting additive. We will be evaluating the safety and immune response in each group. This 15 month study will consist of three vaccinations, 5 office visits, 5 phone calls, and 4 blood draws.

To qualify you must be between the ages of 18-65 and in general good health.

If you are interested in helping develop an Anthrax post-exposure treatment, please give us a call at 615-329-2222 between the hours of 7:30AM - 4:30 PM Monday through Thursday and 7:30AM - 1:00 PM on Friday. Or click PARTICIPATE button at top right. Participants will be compensated for time and travel.